Angiotensin II type 1 receptor blockade: A new development in cardiovascular pharmacology

International Journal of Clinical Practice

Volumn 52, Issue 7, 1998, Pages 475-481

  Leary, A C ^a   Macdonald, T M ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE;

ARTICLE; BLOOD PRESSURE REGULATION; CONGESTIVE HEART FAILURE; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; ELECTROLYTE BALANCE; ESSENTIAL HYPERTENSION; FLUID BALANCE; HEART INFARCTION; HOMEOSTASIS; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; HEART FAILURE, CONGESTIVE; HUMANS; HYPERTENSION; LOSARTAN; RECEPTORS, ANGIOTENSIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 0031763021     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (97)

1. Sealy JE, Laragh JH, Laragh JH, Brenner BM, Eds. Hypertension: pathophysiology, diagnosis and management. New York: Raven Press; 1990; 1287-1317.
2. Vallotton MB. The renin-angiotensin system. Trends Pharmacol Sci 1987; 8: 69-74.
3. Case DB, Atlas SA, Marion RM, Laragh JH. Long-term effects of captopril in renovascular and essential hypertension. Am J Cardiol 1982; 49: 1440-1446.
4. The CONSENSUS Trial Study Group. Effect of enalapril on mortality and severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study. New Engl J Med 1987; 316: 1429-1435.
5. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure. New Engl J Med 1991: 325: 293-302.
6. Chaturvedi N, Sjolie AK, Stephenson JM et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet 1998; 351(9095): 28-31.
7. Clozel J-P, Fischli W. Comparative effects of three different potent renin inhibitors in primates. Hypertension 1993; 22: 9-17.
8. Chiu AT, McCall DE, Price WA Jr et al. Nonpeptide angiotensin II receptor antagonists, VII: cellular and biochemical pharmacology of DuP 753, an orally active antihypertensive agent. J Pharmacol Exp Ther 1990; 252: 711-718.
9. Wong PC, Price WA Jr, Chiu AT. Nonpeptide angiotensin II receptor antagonists: studies with EXP9270 and DuP 753. Hypertension 1990; 15: 823-834.
10. Liao Y, Husain A. The chymase-angiotensin system in humans: biochemistry, molecular biology and potential role in cardiovascular diseases. Can J Cardiol 1995; 11(suppl F): 13-19.
11. Johnston CI. Renin-angiotensin system: a dual tissue and hormonal system for cardiovascular control. J Hypertens 1992; 10(suppl): S13-S26.
12. Dzau VJ. Tissue renin-angiotensin system in myocardial hypertrophy and failure. Arch Intern Med 1993; 153: 937-942.
13. Kurtz A, Scholz H, Della-Bruna R. Molecular mechanism of renin release. J Cardiovasc Pharmacol 1990; 16(suppl 4): 51-57.
14. Dzau VJ, Gibbons GH, Pratt RE. Molecular mechanisms of vascular renin-angiotensin system in myointimal hyperplasia. Hypertension 1991; 18(suppl II): 100-105.
15. Griffin SA, Brown WC, MacPherson F et al. Angiotensin II causes vascular hypertrophy in part by a non-pressor mechanism. Hypertension 1991; 17: 626-635.
16. Bauer JH, Reams GP. The angiotensin II type 1 receptor antagonists: a new class of antihypertensive drugs. Arch Intern Med 1995; 155: 1361-1368.
17. Peach MJ, Dostal DE. The angiotensin II receptor and the actions of angiotensin II. J Cardiovasc Pharmacol 1990; 16(suppl): S25-S30.
18. Mukoyama M, Nakajima M, Horiuchi M et al. Expression cloning of type 2 angiotensin II receptor reveals a unique class of seven-transmembrane receptors. J Biol Chem 1993; 268: 24539-24542.
19. Murphy TJ, Alexander RW, Griendling KK et al. Isolation of a cDNA encoding the vascular type-1 angiotensin II receptor. Nature 1991; 351: 233-236.
20. Sasamura H, Mein L, Krieger JE, Pratt RE et al. Cloning, characterization, and expression of two angiotensin receptor (AT-1) isoforms from the mouse genome. Biochem Biophys Res Comm 1992; 185: 253-259.
21. Bergsma DJ, Ellis C, Kumar C et al. Cloning and characterization of a human angiotensin II type 1 receptor. Biochem Biophys Res Comm 1992; 183: 989-995.
22. Catt KJ, Sandberg K, Balla T et al, Eds. Cellular and molecular biology of the renin-angiotensin system. Boca Raton, Florida; CRC Press; 1993; 307-356.
23. Tsuda T, Griendling KK, Ollerenshaw JD et al. Angiotensin II- and endothelin-induced protein phosphorylation in cultured vascular smooth muscle cells. J Vasc Res 1993; 30: 241-249.
24. Bernstein KE, Berk BC. The biology of angiotensin II receptors. Am J Kidney Dis 1993; 22: 745-754.
25. Griendling KK, Alexander RW. The angiotensin (AT1) receptor. Semin Nephrol 1993; 13: 558-566.
26. Timmermans PBMWM, Wong PC, Chiu AT. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993; 45: 205-251.
27. Gibbons GH, Dzau VJ. The emerging concept of vascular remodelling. New Engl J Med 1994; 330: 1431-1438.
28. Sadoshima J, Izumo S. Molecular characterization of angiotensin II-induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts: critical role of the AT1 receptor subtype. Circ Res 1993; 73: 413-423.
29. Dzau VJ, Mukoyama M, Pratt RE. Molecular biology of angiotensin receptors: target for drug research? J Hypertens 1994; 12: S1-S5.
30. Stoll M, Steckelings UM, Paul M et al. The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest 1995; 95: 651-657.
31. Hanssens M, Keirse MJ, Vankelecom F, Van Assche FA. Fetal and neonatal effects of treatment with angiotensin-converting enzyme inhibitors in pregnancy. Obstet Gynaecol 1991; 78: 128-135.
32. McGiff JC, Crowshank K, Terragno NA, Lonigro AJ. Release of a prostaglandin-like substance into renal venous blood in response to angiotensin II. Circ Res 1970; 27(suppl 1): 121-130.
33. Seyedi N, Xu X, Nasjletti A, Hintze TH. Coronary kinin generation mediates nitric oxide release after angiotensin receptor stimulation. Hypertension 1995; 26: 164-170.
34. Chen L, McNeill JR, Wilson TW, Gopalakrishnan V. Heterogeneity in vascular smooth muscle responsiveness to angiotensin II: role of endothelin. Hypertension 1995; 26: 83-88.
35. Lin L, Nasjletti A. Role of endothelium-derived prostanoid in angiotensin-induced vasoconstriction. Hypertension 1991; 18: 158-164.
36. Reid IA. Interactions between ANG II, sympathetic nervous system, and baroreceptor reflexes in regulation of blood pressure. Am J Physiol 1992; 262: E763-E778.
37. Bonnardeaux A, Davies E, Jeunemaitre X et al. Angiotensin II type 1 receptor gene polymorphisms in human essential hypertension. Hypertension 1994; 24: 63-69.
38. Brunner HR, Gavras H, Laragh JH, Keenan R. Hypertension in man: exposure of the renin and sodium components using angiotensin II blockade. Circ Res 1974; 34(suppl I): 35-43.
39. Pals DT, Masucci FE, Sipos F, Denning GS Jr. A specific competitive antagonist of the vascular action of angiotensin II. Circ Res 1971; 29: 664-672.
40. Streeten DH, Anderson GH, Freiberg JM, Dalakos TG. Use of angiotensin II antagonist (saralasin) in the recognition of 'angiotensinogenic' hypertension. New Engl J Med 1975; 292: 657-662.
41. Timmermans PBMWM, Carini DJ, Chiu AT et al. Angiotensin II receptor antagonists: from discovery to antihypertensive drugs. Hypertension 1991; 18(suppl: III): 36-42.
42. Rhaleb NE, Rouissi N, Nantel F et al. DuP 753 is a specific antagonist for the angiotensin receptor. Hypertension 1991; 17: 480-484.
43. Timmermans PBMWM, Wong PC, Chiu AT, Herblin WF. Nonpeptide angiotensin II receptor antagonists. Trends Pharmacol Sci 1991; 12: 55-62.
44. Goodfriend TL, Elliot ME, Can KJ. Angiotensin receptors and their antagonists. New Engl J Med 1996; 334: 1649-1654.
45. Kang PM, Landau AJ, Eberhardt RT, Frishman WH. Angiotensin II receptor antagonists: a new approach to blockade of the renin-angiotensin system. Am Mean J 1994; 127: 1388-1401.
46. Messerli FH, Weber MA, Brunner HR. Angiotensin II receptor inhibition: a new therapeutic principle. Arch Intern Med 1996; 156: 1957-1965.
47. Timmermans PBMWM, Benfield P, Chiu AT et al. Angiotensin II receptors and functional correlates. Am J Hypertens 1992; 5: 221S-235S.
48. Wong PC, Price WA Jr, Chiu AT et al. In vivo pharmacology of DuP 753. Am J Hypertens 1991;4: 288S-298S.
49. van den Meiracker AH, Admiraal PJJ, Janssen JA et al. Hemodynamic and biochemical effects of the AT1 receptor antagonist Irbesartan in hypertension. Hypertension 1995; 25: 22-29.
50. Wong PC, Price WA Jr, Chiu AT et al. Hypotensive action of DuP 753, and angiotensin II antagonist, in spontaneously hypertensive rats: nonpeptide angiotensin II receptor antagonists, X. Hypertension 1990; 15: 459-468.
51. Bunkenburg B, Schnell C, Baum H-P et al. Prolonged angiotensin II antagonism in spontaneously hypertensive rats: hemodynamic and biochemical consequences. Hypertension 1991; 18: 278-288.
52. Inagami T, Murakami T, Higuchi K, Nakajo S. Roles of renal and vascular renin in spontaneous hypertension and switching of the mechanism upon nephrectomy: lack of hypotensive effects of inhibition of renin, converting enzyme, and angiotensin II receptor blocker after bilateral nephrectomy. Am J Hypertens 1991; 4: 15S-22S.
53. Hajj-ali AF, Zimmerman BG. Kinin contribution to renal vasodilator effect of captopril in rabbit. Hypertension 1991; 17: 504-509.
54. Wong PC, Price WA Jr, Chiu AT et al. Nonpeptide angiotensin II antagonists. IX. Antihypertensive activity in rats of DuP 753, an orally active antihypertensive agent. J Pharmacol Exp Ther 1990; 252: 726-732.
55. Gohlke P, Linz W, Scholkens BA et al. Angiotensin-converting enzyme inhibition improves cardiac function: role of bradykinin. Hypertension 1994;23:411-418.
56. Mizuno K, Tani M, Hashimoto S et al. Effects of losartan, a nonpeptide angiotensin II receptor antagonist, on cardiac hypertrophy and the tissue angiotensin II content in spontaneously hypertensive rats. Life Sci 1992; 51: 367-374.
57. Bunkenburg B, van Amelsvoort T, Rogg H, Wood JM. Receptor-mediated effects of angiotensin II on growth of vascular smooth muscle cells from spontaneously hypertensive rats. Hypertension 1992; 20: 746-754.
58. Bauer JH, Reams GP, Lau A. Effects of losartan on blood pressure, renin-aldosterone, and renal function in essential hypertension. [Abstract] J Am Soc Nephrol 1993; 4: 529.
59. Tsunoda K, Abe K, Hagino T et al. Hypotensive effect of losartan, a nonpeptide angiotensin II receptor antagonist, in essential hypertension. Am J Hypertens 1993; 6: 28-32.
60. Doig JK, McFadyen R, Sweet CS et al. Haemodynamic and renal response to losartan during salt depletion or salt repletion. J Hypertens 1993; 11(suppl 5): S419-S420.
61. Saine DR, Ahrens ER. Renal impairment associated with losartan. Ann Intern Med 1996; 124: 775.
62. Bumier M, Brunner HR. Angiotensin II receptor antagonists and the kidney. Curr Opin Nephrol Hypertens 1994; 3: 537-545.
63. Gansevoort RT, de Zeeuw D, Shahinfar S et al. Effects of the angiotensin II antagonist losartan in hypertensive patients with renal disease. J Hypenens 1994; 12(suppl): S37-S42.
64. Bumier M, Rutshmann B, Nussberger J et al. Salt-dependent renal effects of an angiotensin II antagonist in healthy subjects. Hypertension 1993; 22: 339-347.
65. Ilson B, Boike S, Larouche J et al. The angiotensin II receptor antagonist SB 203220 does not increase uric acid secretion in healthy men. J Am Soc Nephrol 1994; 5: 562.
66. Balla T, Baukal AJ, Eng S, Can KJ. Angiotensin II receptor subtypes and biological responses in the adrenal cortex and medulla. Mol Pharmacol 1991; 40: 401-406.
67. Bauer JH, Reams GP, Wu Z, Lau-Sieckman A. Effects of losartan on the renin-angiotensin-aldosterone axis in essential hypertension. J Human Hypertens 1995; 9(4): 237-243.
68. Goldberg MR, Bradstreet TE, McWilliams EJ et al. Biochemical effects of losartan, a nonpeptide angiotensin II receptor antagonist, on the renin-angiotensin-aldosterone system in hypertensive patients. Hypertension 1995; 25: 37-46.
69. Weinberger MH. Blood pressure and metabolic responses to hydrochlorothiazide, captopril, and the combination in black and white mild-to-moderate hypertensive patients. J Cardiovasc Pharmacol 1985; 7(suppl 1): S52-S55.
70. Doig JK, McFadyen R, Sweet CS et al. Dose-ranging study of the angiotensin type i receptor antagonist losartan (DuP 753/MK 954), in salt-depleted normal man. J Cardiovasc Pharmacol 1993; 21: 732-738.
71. Gavras H, Brunner HR, Turini J et al. Antihypertensive effect of the oral angiotensin-converting enzyme inhibitor SQ 14225 in man. New Engl J Med 1978; 298: 991-995.
72. Grossman E, Peleg E, Carroll J et al. Hemodynamic and humoral effects of the angiotensin II antagonist losartan in essential hypertension. Am J Hypertens 1994; 7: 1041-1044.
73. Chobanian AB, Laragh JH, Brenner BM, Eds. Hypertension: pathophysiology, diagnosis, and management, 2nd edn. New York: Raven Press; 1995; 515-521.
74. Prescott MF, Sawyer WK. ACE inhibition versus angiotensin II, AT1 receptor antagonism: a review of effects on intimai lesion formation in animal model of vascular injury, restenosis and atherosclerosis. Drug Dev Res 1993; 29: 88-93.
75. Huckle WR, Drag MD, Acker WR et al. Effects of subtype-selective and balanced angiotensin II receptor antagonists in a porcine coronary artery model of vascular restenosis. Circulation 1996; 93: 1009-1019.
76. Moan A, Risanger T, Eide I, Kjeldsen SE. The effect of angiotensin II receptor blockade on insulin sensitivity and sympathetic nervous activity in primary hypertension. Blood Press 1994; 3: 185-188.
77. Franke H. Antihypertensive effects of candesartan cilexitil, enalapril and placebo. J Human Hypertens 1997; 11(suppl 2): S61-S62.
78. Gradman AH, Arcuri KE, Goldberg AI et al. A randomized, placebocontrolled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension. Hypertension 1995; 25: 1345-1350.
79. Weber MA, Byyny RL, Pratt JH et al. Blood pressure effects of the angiotensin II receptor blocker, losartan. Arch Intern Med 1995; 155: 405-411.
80. Brunner HR, Christen Y, Munafo A et al. Clinical experience with angiotensin II receptor antagonists. Am J Hypertens 1992; 5: 243S-246S.
81. Weber MA. Clinical experience with the angiotensin II receptor antagonist losartan: a preliminary report. Am J Hypertens 1992; 5: 247S-251S.
82. Larochelle P, Flack JM, Marbury TC et al. Effects and tolerability of irbesartan versus enalapril in patients with severe hypertension. Am J Cardiol 1997; 80(12): 1613-1615.
83. Plouin P-F. Combination therapy with candesartan cilexitil plus hydrochlorothiazide in patients unresponsive to low-dose hydrochlorothiazide. J Human Hypertens 1997; 11(suppl 2): S65-S66.
84. Brunner HR, Delacretaz E, Nussberger J et al. Angiotensin II antagonists DuP 753 and TCV 116. J Hypertens 1994; 12(suppl): S29-S34.
85. Crozier I. Ikram H, Awan N et al. Losartan in heart failure: hemodynamic effects and tolerability. Circulation 1995; 91: 691-697.
86. Lang RM, Elkayam U, Yellen LG et al. Comparative effects of losartan and enalapril on exercise capacity and clinical status in patients with heart failure. J Am Coll Cardiol 1997; 30(4): 983-991.
87. Pitt B, Segal R, Martinez FA et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997; 349(9054): 747-752.
88. Mohabir R, Young SD, Strosberg AM. Role of angiotensin in pressure overload-induced hypertrophy in rats: effects of angiotensin-converting enzyme inhibitors, an AT1 receptor antagonist, and surgical reversal. J Cardiovasc Pharmacol 1994; 23: 291-299.
89. Moric AH, Brown MJ, Lowry R, Higenbottam T. Angiotensin-converting enzyme and the cough reflex. Lancet 1987; 2: 1116-1118.
90. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. New Engl J Med 1992; 327: 685-691.
91. Lindgren BR, Anderson RGG. Angiotensin-converting enzyme inhibitors and their influence on inflammation, bronchial reactivity and cough: a research review. Med Toxicol Adv Drug Exp 1989; 4: 369-380.
92. Lacourciere Y, Brunner HR, Irwin R et al, and the Losartan Cough Study Group. Effects of modulators of the renin-angiotensin-aldosterone system on cough. J Hypertens 1994; 12: 1387-1393.
93. Goldberg AI, Dunlay MC, Sweet CS. Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. Am J Cardiol 1995; 75: 793-795.
94. Hricik DE, Browning PJ, Kopelman R et al. Captopril-induced functional renal insufficiency in patients with bilateral renal artery stenosis or a solitary kidney. New Engl Med 1983; 308: 373-376.
95. Linz W, Wiemer G, Gohlke P et al. Contribution of kinins to the cardio-vascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev 1995; 47: 25-49.
96. Menard J, Chatellier G, Azizi M. Do we need angiotensin II antagonists to treat hypertensive patients? J Human Hypertens 1997; 11(suppl 2): S1-S7.
97. Azizi M, Chatellier G, Guyene T-T et al. Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives. Circulation 1995; 92: 825-834.